BioStock: BioInvent achieves research milestone in partnership with Exelixis
BioInvent has achieved a research milestone in its partnership with Exelixis, focusing on the development of new antibodies for cancer therapy. This achievement unlocks a 1 million USD payment to BioInvent. The company's CEO Martin Welschof expressed satisfaction with the rapid progress of the collaboration while noting that it also serves as further validation for BioInvent's proprietary F.I.R.S.T. and n-CoDeR technologies.
Read the article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/